Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, which encodes dystrophin, a critical protein for maintaining muscle cell membrane integrity. The absence or dysfunction of dystrophin leads to progressive muscle degeneration, weakness, and premature mortality. DMD antibodies are essential tools in research and diagnostics, specifically designed to detect dystrophin or related proteins in biological samples. These antibodies enable the visualization and quantification of dystrophin expression through techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding in disease diagnosis, mechanistic studies, and therapeutic development.
Monoclonal and polyclonal DMD antibodies target specific epitopes of dystrophin or its isoforms, which are valuable for distinguishing between full-length dystrophin and truncated variants (e.g., in Becker muscular dystrophy). They also help evaluate experimental therapies, such as exon-skipping drugs, gene therapy, or CRISPR-based corrections, by assessing dystrophin restoration in preclinical models or patient-derived cells. Additionally, some antibodies detect utrophin, a dystrophin homolog upregulated in DMD as a compensatory mechanism, providing insights into disease progression and potential therapeutic targets. Commercially available DMD antibodies are rigorously validated for specificity, supporting both basic research and clinical applications aimed at mitigating this devastating condition.